Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
“Clinical trials are complex and expensive, and pre-clinical data that helps stratify patients can dramatically increase the likelihood of success during clinical development (Cook et al., 2014; Nelson et al., 2015).”
BackgroundGenome-wide association studies
Uffelmann, E., Huang, Q. Q., Munung, N. S., de Vries, J., Okada, Y., Martin, A. R., Martin, H. C., Lappalainen, T., & Posthuma, D. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00056-9 · Cited by 1,849
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
The druggable genome and support for target identification and validation in drug development
Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1166 · Cited by 1,026
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
“Even programs that are terminated can be “good failures” if the termination has convincingly tested a proposed therapeutic mechanism, a soundly based scientific hypothesis, or provides clear direction for future studies [7].”
BackgroundKing, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
“However, the current in vitro two-dimensional (2D) or three-dimensional (3D) cell culture and in vivo animal experimentation platforms (Figure 1) remain unsatisfactory for an efficient and accurate preclinical evaluation of drug efficacy and toxicity before clinical trials can be approved for testing in human subjects…”
BackgroundUse of Zebrafish in Drug Discovery Toxicology
Cassar, S., Adatto, I., Freeman, J. L., Gamse, J. T., Iturria, I., Lawrence, C., Muriana, A., Peterson, R. T., Van Cruchten, S., & Zon, L. I. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00335 · Cited by 561
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
“Biomarkers can contribute substantially to drug development success [39].”
BackgroundOpen Targets: a platform for therapeutic target identification and validation
Koscielny, G., An, P., Carvalho-Silva, D., Cham, J. A., Fumis, L., Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M., Papa, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1055 · Cited by 504
“Indeed drug development programs that have supporting genetic information are more likely to proceed into the final stages (3,10).”
BackgroundDemystifying traditional herbal medicine with modern approach
Li, F.-S., & Weng, J.-K. (2017) · Nature Plants · doi:10.1038/nplants.2017.109 · Cited by 498
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Open Targets Platform: new developments and updates two years on
Carvalho-Silva, D., Pierleoni, A., Pignatelli, M., Ong, C., Fumis, L., Karamanis, N., Carmona, M., Faulconbridge, A., Hercules, A., McAuley, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1133 · Cited by 472
“These databases can be used to assist with target identification, one of the most important stages in drug discovery (2).”
BackgroundComputational Approaches in Preclinical Studies on Drug Discovery and Development
Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00726 · Cited by 446
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Self-citationGenetics of Inflammatory Bowel Diseases
McGovern, D. P. B., Kugathasan, S., & Cho, J. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.001 · Cited by 431
“These results suggest that an understanding of the genetic architecture of a trait may help streamline the drug discovery process 87 .”
BackgroundAdvancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00885-0 · Cited by 401
Self-citationNanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
“In general, safety failure is the predominant reason of study termination at this stage [62,63].”
BackgroundHickman, J. A., Graeser, R., de Hoogt, R., Vidic, S., Brito, C., Gutekunst, M., van der Kuip, H., & IMI PREDECT consortium (2014) · Biotechnology Journal · doi:10.1002/biot.201300492 · Cited by 380
“In a recent and self-revelatory article addressing some of the current malaise in the pharmaceutical industry and the difficulties of novel drug discovery [1], it was suggested that ultimate project success in drug discovery depended very heavily on the confidence that teams had in studies of target validation.”
BackgroundMedicine in the Fourth Dimension
Cederroth, C. R., Albrecht, U., Bass, J., Brown, S. A., Dyhrfjeld-Johnsen, J., Gachon, F., Green, C. B., Hastings, M. H., Helfrich-Förster, C., Hogenesch, J. B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.019 · Cited by 359
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Bell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327
“Hepatotoxicity remains one of the most frequent causes of compound attrition and late stage failures (Cook et al., 2014).”
BackgroundA Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Self-citationClinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Mills, R. J., Parker, B. L., Quaife-Ryan, G. A., Voges, H. K., Needham, E. J., Bornot, A., Ding, M., Andersson, H., Polla, M., Elliott, D. A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.009 · Cited by 312
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans
Saykin, A. J., Shen, L., Yao, X., Kim, S., Nho, K., Risacher, S. L., Ramanan, V. K., Foroud, T. M., Faber, K. M., Sarwar, N., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.009 · Cited by 306
“[130] Cook D, Brown D, Alexander R, March R, Morgan P,”
BackgroundTutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“Despite intense preclinical safety testing in a number of phase I trials, safety issues may arise which can lead to the termination of a program (Cook et al., 2014; Schuster et al., 2005).”
In silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 289
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
“These results were confirmed by a second analysis of 142 drug R&D projects of AstraZeneca [22].”
BackgroundResultInfluentialPatient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
“In the practical management of large organisations, what is measureable and concrete can often trump that which is opaque and qualitative [65], even if that which is opaque and qualitative is much more important in quantitative terms.”
BackgroundInfluentialSequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Akbari, P., Gilani, A., Sosina, O., Kosmicki, J. A., Khrimian, L., Fang, Y.-Y., Persaud, T., Garcia, V., Sun, D., Li, A., et al. (2021) · Science · doi:10.1126/science.abf8683 · Cited by 276
Zhou, S., Butler-Laporte, G., Nakanishi, T., Morrison, D. R., Afilalo, J., Afilalo, M., Laurent, L., Pietzner, M., Kerrison, N., Zhao, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01281-1 · Cited by 271
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0795-2 · Cited by 262
“Molecular markers such as amyloid PET, cerebrospinal fluid (CSF) Aβ, and CSF tau are frequently employed in the clinical diagnosis of AD, and biomarkers are increasingly recognized as integral components of the drug development pipeline [10].”
BackgroundImproving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
Bergström, C. A. S., & Larsson, P. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.01.044 · Cited by 245
“Only when the ADMET properties of a drug-like compound are of a sufficiently high quality, and when the target has been validated, can the compound be developed into a new medication (Cook et al., 2014; Morgan et al., 2012).”
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
“Approaches such as these when used in other therapeutic areas have improved the rate of success of drug development in other settings [15, 21].”
BackgroundInfluentialTakebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238
In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM
Durán-Iturbide, N. A., Díaz-Eufracio, B. I., & Medina-Franco, J. L. (2020) · ACS Omega · doi:10.1021/acsomega.0c01581 · Cited by 238
Design and demonstration of a pumpless 14 compartment microphysiological system
Miller, P. G., & Shuler, M. L. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25989 · Cited by 238
Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
Improving target assessment in biomedical research: the GOT-IT recommendations
Emmerich, C. H., Gamboa, L. M., Hofmann, M. C. J., Bonin-Andresen, M., Arbach, O., Schendel, P., Gerlach, B., Hempel, K., Bespalov, A., Dirnagl, U., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0087-3 · Cited by 226
Azizgolshani, H., Coppeta, J. R., Vedula, E. M., Marr, E. E., Cain, B. P., Luu, R. J., Lech, M. P., Kann, S. H., Mulhern, T. J., Tandon, V., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00067e · Cited by 225
In vitro models of medulloblastoma: Choosing the right tool for the job
Ivanov, D. P., Coyle, B., Walker, D. A., & Grabowska, A. M. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.07.028 · Cited by 227
Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.219 · Cited by 220
Spanagel, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/rspanagel · Cited by 221
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 220
“Drug development failures can be attributed to gaps in our understanding of the biology underlying human disease, excessive reliance on non-human models, and prioritization of targets or agents with low specificity, poor pharmacology or a propensity to produce unwanted adverse reactions 4,5 .”
BackgroundThe role of mouse tumour models in the discovery and development of anticancer drugs
Ireson, C. R., Alavijeh, M. S., Palmer, A. M., Fowler, E. R., & Jones, H. J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0495-5 · Cited by 218
Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., & Kim, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19313-8 · Cited by 212
Wang, H., Dey, K. K., Chen, P.-C., Li, Y., Niu, M., Cho, J.-H., Wang, X., Bai, B., Jiao, Y., Chepyala, S. R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00384-6 · Cited by 243
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
Harvey, A. L. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.10.020 · Cited by 210
“The reasons for the high attrition rates have been analysed and debated (e.g. Pammolli et al., 2011; Swinney and Anthony, 2011; Allison, 2012; Morgan et al., 2012; Scannell et al., 2012; SamsDodd, 2013; Cook et al., 2014; Eder et al., 2014).”
BackgroundInfluentialImproving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. E. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 206
Savitz, S. I., Baron, J.-C., Fisher, M., for the STAIR X Consortium, Albers, G. W., Arbe-Barnes, S., Boltze, J., Broderick, J., Broschat, K. O., Elkind, M. S. V., et al. (2019) · Stroke · doi:10.1161/strokeaha.118.023927 · Cited by 201
Why Is There No Cure for Tinnitus?
McFerran, D. J., Stockdale, D., Holme, R., Large, C. H., & Baguley, D. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00802 · Cited by 203
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
“Moreover, hepatic liabilities are important cost drivers for the pharmaceutical industry that can result in late-stage attrition of drug candidates or postmarketing withdrawals, as exemplified by bromfenac, troglitazone, ximelagatran, and pemoline (Park et al., 2011; Cook et al., 2014).”
BackgroundMulti-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics
McAleer, C. W., Long, C. J., Elbrecht, D., Sasserath, T., Bridges, L. R., Rumsey, J. W., Martin, C., Schnepper, M., Wang, Y., Schuler, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1386 · Cited by 199
Biomedical Metal–Organic Framework Materials: Perspectives and Challenges
Wang, A., Walden, M., Ettlinger, R., Kiessling, F., Gassensmith, J. J., Lammers, T., Wuttke, S., & Peña, Q. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202308589 · Cited by 188
Toxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Integrating organoids and organ-on-a-chip devices
Zhao, Y., Landau, S., Okhovatian, S., Liu, C., Lu, R. X. Z., Lai, B. F. L., Wu, Q., Kieda, J., Cheung, K., Rajasekar, S., et al. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00207-z · Cited by 185
“However, they still lack appropriate vascularization, routine evaluation of pharmacokinetics and pharmacodynamics, identification of drug tolerization mechanisms and off-target effects 44 .”
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
“Informative POC studies derisk drug development programs and increase the likelihood of success [30].”
BackgroundBisacchi, G. S., & Manchester, J. I. (2015) · ACS Infectious Diseases · doi:10.1021/id500013t · Cited by 180
“during many of those years was an emphasis on high numbers of project transitions (such as achieving Lead Identification or Lead Optimization status).(201) This metrics-based philosophy”
BackgroundVorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
“Importantly, previous analyses indicate that the quality of preclinical safety profiles is in strong anticorrelation with the risk of project closure due to safety issues in clinical stages (Cook et al., 2014), emphasizing that accurate tests for the prediction of DILI in early stages of drug development are of paramo…”
BackgroundPhenome-wide association studies across large population cohorts support drug target validation
Diogo, D., Tian, C., Franklin, C. S., Alanne-Kinnunen, M., March, M., Spencer, C. C. A., Vangjeli, C., Weale, M. E., Mattsson, H., Kilpeläinen, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06540-3 · Cited by 186
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
“This robust NPV is largely based on the low clinical positive prevalence observed in our database and in the literature, which can be attributed to the fact that compounds entering clinical development have typically cleared many safety hurdles via extensive in silico, in vitro, and in vivo lead optimization screening…”
BackgroundLindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., & Conn, P. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00656 · Cited by 181
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 180
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Enhancers in disease: molecular basis and emerging treatment strategies
Claringbould, A., & Zaugg, J. B. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.012 · Cited by 181
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Self-citationDand, N., Mahil, S., Capon, F., Smith, C., Simpson, M., & Barker, J. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3384 · Cited by 178
“Indeed, it has been shown in general that pipeline drugs whose mechanisms are supported by direct genetic evidence are more likely to reach the clinic (53, 54).”
BackgroundOleaga, C., Riu, A., Rothemund, S., Lavado, A., McAleer, C. W., Long, C. J., Persaud, K., Narasimhan, N. S., Tran, M., Roles, J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.062 · Cited by 175
“The regulatory context of March 2013 requires efforts for alternative methods to assess systemic toxicity in the field of cosmetic ingredients, as well as drugs due to the poor human toxicology prediction [1-7].”
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
“Drugs that have genetic connections to the neurobiology of the disease and that have biomarkers to inform drug development decisions are more likely to advance from one phase to the next than drugs that lack this information [57].”
BackgroundVorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk
Chen, W. L. K., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., Shockley, M., Large, E. M., Venkataramanan, R., Hughes, D. J., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26370 · Cited by 172
“As a result, drug attrition in Phase II and III clinical trials is now attributed mainly to a lack of clinical efficacy rather than toxicity (Cook et al., 2014; Denayer et al., 2014; Kubinyi, 2003).”
BackgroundKinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169
On the predictive utility of animal models of osteoarthritis
Malfait, A.-M., & Little, C. B. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0747-6 · Cited by 166
“strongest preclinical evidence (20 %) [8].”
BackgroundInfluentialAlmqvist, H., Axelsson, H., Jafari, R., Dan, C., Mateus, A., Haraldsson, M., Larsson, A., Molina, D. M., Artursson, P., Lundbäck, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11040 · Cited by 160
Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., Patterson, N. L., & McMullen, J. R. (2018) · Physiological Reviews · doi:10.1152/physrev.00043.2016 · Cited by 160
Cardiovascular organ-on-a-chip platforms for drug discovery and development
Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161
Rational Cell Culture Optimization Enhances Experimental Reproducibility in Cancer Cells
Wright Muelas, M., Ortega, F., Breitling, R., Bendtsen, C., & Westerhoff, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-21050-4 · Cited by 160
Kell, D. B., & Oliver, S. G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00231 · Cited by 169
Diogo, D., Bastarache, L. A., Liao, K. P., Graham, R., Fulton, R. S., Greenberg, J. D., Eyre, S., Bowes, J., Cui, J., Lee, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122271 · Cited by 156
“We have previously proposed three features of human genetics that can be applied to drug discovery [20]: (1) identification of targets that, when perturbed in a manner that mimics traitassociated alleles, demonstrate efficacy in treating complex human diseases—as illustrated by recent studies highlighting the increase…”
BackgroundKidney-based in vitro models for drug-induced toxicity testing
Faria, J., Ahmed, S., Gerritsen, K. G. F., Mihaila, S. M., & Masereeuw, R. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02598-0 · Cited by 168
Biological and functional multimorbidity—from mechanisms to management
Langenberg, C., Hingorani, A. D., & Whitty, C. W. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02420-6 · Cited by 164
The genetics of diabetic complications
Ahlqvist, E., van Zuydam, N. R., Groop, L., & McCarthy, M. I. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.37 · Cited by 162
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Walkup, G. K., You, Z., Ross, P. L., Allen, E. K. H., Daryaee, F., Hale, M. R., O’Donnell, J. C., Ehmann, D. E., Schuck, V., Buurman, E. T., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1796 · Cited by 160
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.